By targeting CXCL10 with ‎CRISPR, researchers can fine-tune ‎‎immune responses and specifically inhibit angiogenesis, ‎leading to a more controlled and tumor-‎specific therapeutic effect. The gene discussed is CXCL10; the disease is neoplasm.